5 news items
Peeling Back The Layers: Exploring Natera Through Analyst Insights
NTRA
27 Aug 24
), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving
Forecasting The Future: 6 Analyst Projections For Natera
NTRA
9 Aug 24
0
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target
New MultiCenter Prospective Study Demonstrates Signatera's Clinical Utility in Merkel Cell Carcinoma
NTRA
26 Jul 24
included 319 patients with stage I-IV MCC. Signatera was used to assess ctDNA levels at the time of enrollment, and every 3 months during the surveillance
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
NTRA
17 Jun 24
assessment for both antibody mediated rejection (AMR) and acute cellular rejection (ACR).
"Over
Breaking Down Natera: 10 Analysts Share Their Views
NTRA
3 Jun 24
circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera
- Prev
- 1
- Next